Last reviewed · How we verify
NCT04498819: STAND-VAT
Wearable Technology and a Virtual Lifestyle Program for Type 2 Diabetics
NA trial testing Wearable Activity Trackers, Exercise Prescription and Virtual Care in Type 2 Diabetes in 10 participants. Completed in 7 May 2021.
2 April 2021
Quick facts
| Lead sponsor | Western University, Canada |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 10 |
| Start date | 9 November 2020 |
| Primary completion | 2 April 2021 |
| Estimated completion | 7 May 2021 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Wearable Activity Trackers, Exercise Prescription and Virtual Care
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Comorbidities and Coexisting Conditions — all drugs for Comorbidities and Coexisting Conditions →
Sponsor
Western University, Canada
Who can join
18 and older, any sex, with Type 2 Diabetes or Comorbidities and Coexisting Conditions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Primary Care Diabetes Support Program (PCDSP) offers a lifestyle medicine program, STAND, that patients can self-select themselves to participate. STAND offers biweekly, one-hour educational classes. With the onset of COVID-19, the clinic has moved virtually, but has yet to offer an individualized exercise program. Little evidence is available on utilizing telemedicine and wearable technologies combined in a clinical exercise setting. This is a 6-week single cohort prospective study assessing the feasibility of incorporating wearable activity trackers and individualized exercise prescriptions in the PCDSP's virtually delivered, STAND program in an adult population with type 2 diabetes mellitus. Roughly 15-20 participants will be recruited. Participants will attend the bi-weekly STAND classes and track their step counts daily using FitBits, trying to achieve individually prescribed step counts. Participants receive a brief follow up phone call every other week. The primary outcomes assessed will be recruitment and retention rates, as well as acceptability of, and adherence to, the virtual program. Acceptability will be assessed by an exit survey and mean number of reported technological issues. Adherence will be number of classes attended and percent of days with FitBit worn (\>500 steps) and average percent Libre sensor is active. Change in self-efficacy levels, diabetes emotional related distress, exercise volume, glucose control and fitness levels will secondarily be assessed.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Examining a Remote Group-Based Type 2 Diabetes Self-Management Education Program in the COVID-19 Era Using the ORBIT Model: Small 6-Week Feasibility Study.
Hiemstra MS, Reichert SM, Mitchell MS. · · 2024 · PMID 38285502 · DOI 10.2196/46418
Verify or expand the search:
- PubMed search for NCT04498819
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Western University, Canada trials
Trials by the same sponsor.
- NCT07485062 — Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes · Phase 4 · not yet recruiting
- NCT07372755 — Feasibility and Usability of a Mobile App for Monitoring and Managing Functional Movement Disorders · not yet recruiting
- NCT07302308 — Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders. · not yet recruiting
- NCT04323423 — The DURATION Study: reDUcing sedentaRy behAviour to Maintain cogniTIve functiON. · NA · withdrawn
- NCT07204301 — Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Pat · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04498819 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Western University, Canada
- Last refreshed: 6 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04498819.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing